Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study.

Trial Profile

Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2009

At a glance

  • Drugs Tanezumab; Tanezumab
  • Indications Back pain; Cancer pain; Musculoskeletal pain; Neuralgia; Pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Planned number of patients changed from 72 to 76 as reported by ClinicalTrials.gov.
    • 06 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top